PMID- 20139775
OWN - NLM
STAT- MEDLINE
DCOM- 20100614
LR  - 20171116
IS  - 1537-4513 (Electronic)
IS  - 1524-9557 (Linking)
VI  - 33
IP  - 2
DP  - 2010 Feb-Mar
TI  - Dendritic cells (DCs) can be successfully generated from leukemic blasts in 
      individual patients with AML or MDS: an evaluation of different methods.
PG  - 185-99
LID - 10.1097/CJI.0b013e3181b8f4ce [doi]
AB  - Myeloid-leukemic cells (AML, MDS, CML) can be differentiated to leukemia-derived 
      dendritic cell [DC (DCleu)] potentially presenting the whole leukemic antigen 
      repertoire without knowledge of distinct leukemia antigens and are regarded as 
      promising candidates for a vaccination strategy. We studied the capability of 6 
      serum-free DC culture methods, chosen according to different mechanisms, to 
      induce DC differentiation in 137 cases of AML and 52 cases of MDS. DC-stimulating 
      substances were cytokines ("standard-medium", "MCM-Mimic", "cytokine-method"), 
      bacterial lysates ("Picibanil"), double-stranded RNA ["Poly (I:C)"] or a cytokine 
      bypass method ("Ca-ionophore"). The quality/quantity of DC generated was 
      estimated by flow cytometry studying (co) expressions of "DC"antigens, 
      costimulatory, maturation, and blast-antigens. Comparing these methods on average 
      15% to 32% DC, depending on methods used, could be obtained from blast-containing 
      mononuclear cells (MNC) in AML/MDS cases with a DC viability of more than 60%. In 
      all, 39% to 64% of these DC were mature; 31% to 52% of leukemic blasts could be 
      converted to DCleu and DCleu-proportions in the suspension were 2% to 70% (13%). 
      Average results of all culture methods tested were comparable, however not every 
      given case of AML could be differentiated to DC with 1 selected method. However 
      performing a pre-analysis with 3 DC-generating methods (MCM-Mimic, Picibanil, 
      Ca-ionophore) we could generate DC in any given case. Functional analyses 
      provided proof, that DC primed T cells to antileukemia-directed cytotoxic cells, 
      although an anti-leukemic reaction was not achieved in every case. In summary our 
      data show that a successful, quantitative DC/DCleu generation is possible with 
      the best of 3 previously tested methods in any given case. Reasons for different 
      functional behaviors of DC-primed T cells must be evaluated to design a 
      practicable DC-based vaccination strategy.
FAU - Kremser, Andreas
AU  - Kremser A
AD  - Medical Department III, University Hospital Grosshadern, 
      Ludwig-Maximilians-University, 81377 Munich, Germany.
FAU - Dressig, Julia
AU  - Dressig J
FAU - Grabrucker, Christine
AU  - Grabrucker C
FAU - Liepert, Anja
AU  - Liepert A
FAU - Kroell, Tanja
AU  - Kroell T
FAU - Scholl, Nina
AU  - Scholl N
FAU - Schmid, Christoph
AU  - Schmid C
FAU - Tischer, Johanna
AU  - Tischer J
FAU - Kufner, Stefanie
AU  - Kufner S
FAU - Salih, Helmut
AU  - Salih H
FAU - Kolb, Hans Jochem
AU  - Kolb HJ
FAU - Schmetzer, Helga
AU  - Schmetzer H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Antigens, Differentiation)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Culture Media, Serum-Free)
RN  - 0 (Cytokines)
RN  - 39325-01-4 (Picibanil)
RN  - O84C90HH2L (Poly I-C)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigen Presentation/drug effects
MH  - Antigens, Differentiation/metabolism
MH  - Antigens, Neoplasm/immunology/metabolism
MH  - *Cancer Vaccines
MH  - Cell Culture Techniques/*methods
MH  - Cell Differentiation/drug effects
MH  - Cell Separation
MH  - Culture Media, Serum-Free
MH  - Cytokines/metabolism/pharmacology
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/drug effects/immunology/metabolism/*pathology
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Leukemia, Myeloid, Acute/immunology/*pathology/therapy
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/immunology/*pathology/therapy
MH  - Picibanil/pharmacology
MH  - Poly I-C/pharmacology
MH  - T-Lymphocytes, Cytotoxic/immunology
EDAT- 2010/02/09 06:00
MHDA- 2010/06/15 06:00
CRDT- 2010/02/09 06:00
PHST- 2010/02/09 06:00 [entrez]
PHST- 2010/02/09 06:00 [pubmed]
PHST- 2010/06/15 06:00 [medline]
AID - 10.1097/CJI.0b013e3181b8f4ce [doi]
PST - ppublish
SO  - J Immunother. 2010 Feb-Mar;33(2):185-99. doi: 10.1097/CJI.0b013e3181b8f4ce.